CMTx Biotech is a clinical-stage biopharmaceutical company that is aggressively developing an orally-administered small molecule for the treatment of COVID-19 patients. The company is currently preparing to advance into a Phase II clinical trial to demonstrate the safety and efficacy of our lead drug candidate in hospitalized COVID-19 patients.
Our clinical-stage drug candidate has already demonstrated impressive efficacy in a number of animal models of acute respiratory distress syndrome (ARDS) across multiple species (rats, mice, pigs, sheep). It has also been evaluated in several Phase I/II clinical studies, which showed that the drug is well-tolerated.
CMTx Biotech also has a pipeline of pre-clinical stage analogues for the treatment of rare diseases.